WO2023165015A1 - 特异性靶向肿瘤的近红外荧光探针及其合成方法和应用 - Google Patents

特异性靶向肿瘤的近红外荧光探针及其合成方法和应用 Download PDF

Info

Publication number
WO2023165015A1
WO2023165015A1 PCT/CN2022/091632 CN2022091632W WO2023165015A1 WO 2023165015 A1 WO2023165015 A1 WO 2023165015A1 CN 2022091632 W CN2022091632 W CN 2022091632W WO 2023165015 A1 WO2023165015 A1 WO 2023165015A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluorescent probe
infrared fluorescent
specifically targeting
probe specifically
targeting tumors
Prior art date
Application number
PCT/CN2022/091632
Other languages
English (en)
French (fr)
Inventor
蔡惠明
Original Assignee
南京诺源医疗器械有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京诺源医疗器械有限公司 filed Critical 南京诺源医疗器械有限公司
Priority to EP22754275.0A priority Critical patent/EP4269407A1/en
Publication of WO2023165015A1 publication Critical patent/WO2023165015A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1003—Carbocyclic compounds
    • C09K2211/1007—Non-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom

Definitions

  • the invention belongs to the technical field of specific molecular targeting diagnostic reagents, and in particular relates to a diagnostic reagent complex composed of a near-infrared fluorescent dye, a linker molecule and a small molecule inhibitor lapatinib.
  • cancer is one of the chief culprits that seriously endanger the health of residents in my country except cardiovascular diseases, and seriously endanger human health.
  • the clinical treatment of tumors mainly includes surgical resection, chemotherapy drugs, radiotherapy drugs and so on.
  • surgical resection is one of the best treatments for all solid tumors. Effective surgical resection can greatly prolong the survival period of patients.
  • various advanced instruments and equipment such as MRI, ultrasound imaging, Spect/CT imaging, etc., can accurately locate tumors, find out the location of the lesion, and then carry out targeted treatment.
  • Near-infrared fluorescence imaging with a wave band between 650-900nm, has good penetrating power, strong anti-interference, low cost, and can be used during surgery to provide surgeons with a clearer field of vision, so that tumors can be removed more accurately .
  • ICG Indocyanine Green
  • the specifically targeted fluorescent probe accumulates specifically in the tumor site after administration, and stays in the tumor for a long time, while normal tissues can be quickly cleared, and can be better surgically removed during the surgeon's operation.
  • Lapatinib is a marketed antineoplastic drug, which belongs to tyrosine kinase inhibitor, targets Her2, and is used for the treatment of breast cancer and colorectal cancer.
  • Lapatinib can specifically target tumor tissue, activate pathways to further lead to tumor cell apoptosis, and play a role in tumor therapy.
  • it is an anti-tumor drug with tumor-specific killing effect It has a certain research value and can be used for the development of specific fluorescent probes, further expanding the application value of drugs, for surgical navigation, and to remove tumors.
  • the object of the present invention is to provide a near-infrared fluorescent probe specifically targeting tumors and its synthesis method and application.
  • the present invention adopts the following technical solutions:
  • a near-infrared fluorescent probe specifically targeting tumors which is a compound represented by the following formula I or a pharmaceutically acceptable salt thereof:
  • Y is a dye molecule with fluorescence excitation and emission spectra in the near-infrared (NIR) range, and the compound represented by formula I or a pharmaceutically acceptable salt thereof can maintain or enhance the fluorescence of the dye molecule Y.
  • NIR near-infrared
  • the linking molecule is selected from PEG4, PEG6, 6-aminocaproic acid, glycine (G3, G6), PEG4-glycine, and its structural formula is as follows:
  • the dye molecule Y is selected from the following structures:
  • a method for synthesizing a near-infrared fluorescent probe specifically targeting tumors comprising the following steps:
  • Step a mixing in the presence of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), base and polar solvent Patinib and X;
  • HATU 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • Step b drop the product obtained in step a into water, extract and concentrate, add trifluoroacetic acid to remove the BOC protecting group, and concentrate to obtain the lapatinib-X intermediate compound;
  • Step c mixing in the presence of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), base and polar solvent Patinib-X intermediate compound and dye molecule Y;
  • HATU 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • step d the product obtained in step c is purified by preparative liquid phase to obtain the target compound lapatinib-X-Y, which is the near-infrared fluorescent probe.
  • the polar solvent is one or more of N,N-dimethylformamide (DMF), anhydrous dimethylsulfoxide (DMSO), and N-methylpyrrolidone.
  • the base is one or more of triethylamine (TEA) and N,N-diisopropylethylamine (DIEA).
  • TAA triethylamine
  • DIEA N,N-diisopropylethylamine
  • the near-infrared fluorescent probe specifically targeting tumors is used in the preparation of tumor diagnostic reagents.
  • the tumor is one or more of liver cancer, breast cancer, lung cancer, pancreatic cancer, and colorectal cancer.
  • the specific tumor-targeting near-infrared fluorescent probe provided by the present invention can actively target the tumor site, and does not accumulate in normal tissues or be cleared in a short time, thereby not affecting its clinical application.
  • the near-infrared fluorescent probe of the present invention can be quickly cleared in normal tissues, but stays in tumor sites for a long time, so as to achieve the function of in vivo diagnosis, has a certain clinical application prospect, and is applied to clinical intraoperative navigation.
  • Fig. 1 is the YQ-H-01 absorption spectrum that embodiment prepares
  • Fig. 2 is the fluorescent spectrum such as YQ-H-01 that embodiment prepares;
  • Fig. 3 is the in vivo imaging of YQ-H-01 etc. prepared in the embodiment in colorectal cancer HT29 tumor-bearing mice;
  • Fig. 4 is the in vivo imaging of the YQ-H-06 probe prepared in the example in pancreatic cancer PANC1, liver cancer Hepg2, and lung cancer H460 tumor-bearing mice.
  • Embodiment 1 the synthesis of YQ-H-01
  • Lapatinib (5mg, 1.0eq), ICG-02 (12mg, 1.5eq), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea Fluorophosphate (HATU, 13mg, 4.0eq), triethylamine (6ul, 5.0eq), reacted at room temperature in the dark for 3 hours, and monitored the reaction by HPLC.
  • Embodiment 2 the synthesis of YQ-H-03
  • acetic acid Extract with ethyl ester
  • Embodiment 3 the synthesis of YQ-H-04
  • Embodiment 4 the synthesis of YQ-H-05
  • Embodiment 5 the synthesis of YQ-H-06
  • Embodiment 6 the synthesis of YQ-H-07
  • Embodiment 7 the synthesis of YQ-H-08
  • the YQ-H (30nmol, dissolved in 100uL of normal saline for injection) series probes were administered through the tail vein, and the small animal live imaging CCD was used to capture fluorescence images at different time points, followed by 0h (given Pre-drug), 6h, 12h, 24h, 48h, the results showed that in HT29 tumor-bearing mice, the probe YQ-H-01/03 had a certain tumor targeting effect and had a strong fluorescent signal in the liver, etc., which may not be Conducive to the development of subsequent probes; the probe YQ-H-08 introduces an aromatic benzene ring structure between the targeting molecule lapatinib and the fluorescent dye, which enhances tumor uptake to a certain extent and also leads to obvious systemic signals in mice.
  • the probe YQ-H-04/06/07 showed better metabolism characteristics in vivo, the fluorescence signal in the liver was significantly reduced, and the fluorescence signal in the tumor was obvious.
  • the effect of targeting YQ-H-06 tumors is better, and it has the potential for subsequent development.
  • the present invention verified the tumor targeting of the probe YQ-H-06 in pancreatic cancer (PANC1), liver cancer (HepG2), and lung cancer (H460) tumor-bearing mice, and found that the probe YQ-H-06 was in the three Subtesticular tumor-bearing mice also have a good tumor targeting effect, and further research and development are needed in order to be applied to clinical surgical navigation.
  • PANC1 pancreatic cancer
  • HepG2 liver cancer
  • lung cancer H460

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明公开了一种特异性靶向肿瘤的近红外荧光探针及其合成方法和应用，其为下式Ⅰ所示的化合物或其药学可接受的盐：其中：X是连接分子，选自无、PEGn、甘氨酸(Gm)，n＝0-10，m＝0-10，连接分子的一端为氨基，另一端为羧基；Y是在近红外(NIR)范围内具有荧光激发和发射光谱的染料分子,且式Ⅰ所示的化合物或其药学可接受的盐能够维持或增强染料分子Y的荧光。本发明的近红外荧光探针在正常组织内能迅速清除，而在肿瘤部位长时间滞留，从而能达到活体诊断的作用，具备一定的临床应用前景，应用于临床术中导航。

Description

特异性靶向肿瘤的近红外荧光探针及其合成方法和应用 技术领域
本发明属于特异性分子靶向诊断试剂技术领域，具体涉及近红外荧光染料、连接分子和小分子抑制剂拉帕替尼组成的诊断试剂复合物。
背景技术
目前，癌症是除心血管疾病外严重危害我国居民健康的罪魁祸首之一，严重危害着人类的健康。临床上对于肿瘤的治疗主要有外科手术切除、化疗药物、放疗药物等。其中手术切除是所有实体瘤的最佳疗法之一，有效的手术切除，能极大的延长患者的生存期。近年来各种先进仪器设备的出现，如核磁共振成像、超声成像、Spect/CT造影等，能精准的定位肿瘤，找出病灶所在部位，再进行针对性的治疗。近红外荧光成像，波段在650-900nm之间，具有良好的穿透力，抗干扰强，成本低，能在手术过程中使用，为外科医生提供更清晰的视野，从而能够更精确的切除肿瘤。
吲哚菁绿(ICG)是经FDA获批的近红外荧光染料，能与血浆蛋白结合，经EPR效应集聚到肿瘤部位，一般手术前一天以静脉给药，经一天代谢后，第二天进行手术，体内肝肠基本清除干净，从而不会对手术产生干扰，存在的问题就是需要提前一天给药，走肝肠代谢，不利于肝脏、肠肿瘤成像，ICG容易产生假阳性。为避免这种假阳性的发生，需具有开发出经肾脏代谢的特异性靶向的荧光探针，从而具有更普遍的应用前景。特异性靶向的荧光探针，给药后特异性积聚于肿瘤部位，在肿瘤中滞留时间较长，而正常组织能迅速清除，在外科医生手术过程中，能更好的进行手术切除。
拉帕替尼是一个已上市的抗肿瘤药物，属于酪氨酸激酶抑制剂，靶点为Her2，用于乳腺癌、结直肠癌治疗。拉帕替尼能特异性靶向肿瘤组织，激活通路进一步导致肿瘤细胞凋亡，起到肿瘤治疗作用，在开发具有肿瘤特异性的荧光探针过程中，具有肿瘤特异性杀伤作用的抗肿瘤药物具备一定的研究价值，可用于特异性荧光探针的开发，进一步扩大药物的应用价值，用于外科手术导航，切除肿瘤。
发明内容
为解决上述现有技术中存在的问题，本发明的目的是提供一种特异性靶向肿瘤的近红外荧光探针及其合成方法和应用。
为实现上述目的，本发明采用如下技术方案：
一种特异性靶向肿瘤的近红外荧光探针，其为下式Ⅰ所示的化合物或其药学可接受的盐：
Figure PCTCN2022091632-appb-000001
其中：
X是连接分子，选自无、PEG n、甘氨酸(G m)，n＝0-10，m＝0-10，连接分子的一端为氨基，另一端为羧基；
Y是在近红外(NIR)范围内具有荧光激发和发射光谱的染料分子,且式Ⅰ所示的化合物或其药学可接受的盐能够维持或增强染料分子Y的荧光。
所述连接分子选自PEG4、PEG6、6-氨基己酸、甘氨酸(G3、G6)、PEG4-甘氨酸，结构式如下：
Figure PCTCN2022091632-appb-000002
所述染料分子Y选自以下结构：
Figure PCTCN2022091632-appb-000003
一种特异性靶向肿瘤的近红外荧光探针的合成方法，包括以下步骤：
步骤a，在2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)、碱和极 性溶剂的存在下混合拉帕替尼和X；
步骤b，将步骤a得到的产物滴到水中，萃取后浓缩，再加三氟乙酸脱BOC保护基，浓缩得到拉帕替尼-X中间体化合物；
步骤c，在2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)、碱和极性溶剂的存在下混合拉帕替尼-X中间体化合物和染料分子Y；
步骤d，将步骤c得到的产物以制备液相纯化，得到目标化合物拉帕替尼-X-Y，即为所述近红外荧光探针。
所述步骤a和c中，极性溶剂为N,N-二甲基甲酰胺(DMF)、无水二甲基亚砜(DMSO)、N-甲基吡咯烷酮的一种或多种。
所述步骤a和c中，碱为三乙胺(TEA)、N,N-二异丙基乙胺(DIEA)的一种或多种。
所述的特异性靶向肿瘤的近红外荧光探针在制备肿瘤诊断试剂中应用。
所述的特异性靶向肿瘤的近红外荧光探针在制备肿瘤精准手术导航的活体荧光成像试剂中的应用。
所述肿瘤为肝癌、乳腺癌、肺癌、胰腺癌、结直肠癌的一种或多种。
有益效果：本发明提供的特异性肿瘤靶向的近红外荧光探针，能主动靶向到肿瘤部位，在正常组织中不集聚或短时间清除干净，从而不影响其临床应用。本发明的近红外荧光探针在正常组织内能迅速清除，而在肿瘤部位长时间滞留，从而能达到活体诊断的作用，具备一定的临床应用前景，应用于临床术中导航。
附图说明
图1为实施例制备的YQ-H-01等吸收光谱；
图2为实施例制备的YQ-H-01等荧光光谱；
图3为实施例制备的YQ-H-01等在结直肠癌HT29荷瘤鼠中的体内成像；
图4为实施例制备的YQ-H-06探针分别在胰腺癌PANC1、肝癌Hepg2、肺癌H460荷瘤鼠中的体内成像。
具体实施方式
下面结合实施例对本发明做更进一步的解释。
根据下述实施例，可以更好的理解本发明。然而，本领域的技术人员容易理解，实施例所描述的具体的物料配比、工艺条件及其结果仅用于说明本发明，而不应当也不会限制权利要求书中所详细描述的本发明。
实施例1：YQ-H-01的合成
Figure PCTCN2022091632-appb-000004
拉帕替尼(5mg，1.0eq)、ICG-02(12mg，1.5eq)、2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU，13mg，4.0eq)、三乙胺(6ul，5.0eq)，避光室温反应3小时，以HPLC监测反应，反应完全后，以制备液相纯化，目标馏分冻干后得绿色固体YQ-H-01(5mg，Y＝38.9％)，经质谱和核磁氢谱确证，m/z＝， 1H NMR(300MHz,DMSO)δ8.88(dd,J＝15.1,10.5Hz,2H),8.66(t,J＝12.4Hz,2H),8.24(dd,J＝11.1,6.4Hz,1H),8.01(t,J＝2.8Hz,1H),7.85-7.66(m,4H),7.60-7.45(m,3H),7.42-7.16(m,7H),6.52(dt,J＝24.9,7.5Hz,3H),5.34(s,2H),4.64(s,2H),4.26(d,J＝7.2Hz,4H),3.39(t,J＝8.0Hz,2H),3.17(s,2H),3.04(d,J＝9.4Hz,4H),2.73-2.59(m,8H),2.55(s,3H),2.07-1.88(m,4H),1.78-1.65(m,2H),1.58(d,J＝7.6Hz,12H).
实施例2：YQ-H-03的合成
Figure PCTCN2022091632-appb-000005
拉帕替尼(10mg，1.0eq)、6-Boc-氨基己酸(8mg，2eq)、2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU，13mg，2.0eq)、三乙胺(7.2ul，3.0eq)，室温反应1小时，TLC监测反应，待反应完全后，将反应液滴入水中，再以乙酸乙酯萃取，合并有机层浓缩后加三氟乙酸脱Boc，同样以TLC监测反应，反应完全后，将三氟乙酸蒸除后，纯化得连上6-氨基己酸的拉帕替尼，后续参照化合物YQ-H-01的合成，得目标化合物YQ-H-03，绿色固体，结构经质谱核磁氢谱确证，m/z＝， 1H NMR(300MHz,DMSO)δ8.88(dd,J＝15.1,10.5Hz,2H),8.66(t,J＝12.4Hz,2H),8.24(dd,J＝11.1,6.4Hz,1H),8.01(t,J＝2.8Hz,1H),7.85-7.66(m,4H),7.60-7.45(m,3H),7.42-7.16(m,7H),6.52(dt,J＝24.9,7.5Hz,3H),5.34(s,2H),4.64(s,2H),4.26(d,J＝7.2Hz,4H),3.39(t,J＝8.0Hz, 2H),3.17(s,2H),3.04(d,J＝9.4Hz,4H),2.73-2.59(m,8H),2.55(s,3H),2.07-1.88(m,4H),1.78-1.65(m,2H),1.58(d,J＝7.6Hz,12H)。
实施例3：YQ-H-04的合成
Figure PCTCN2022091632-appb-000006
合成方法参考YQ-H-03，结构经质谱和核磁氢谱确证，m/z＝， 1H NMR(300MHz,DMSO)δ8.96(dd,J＝8.0,4.8Hz,2H),8.66(d,J＝14.0Hz,2H),8.36(d,J＝8.9Hz,1H),8.01-7.88(m,3H),7.75(d,J＝1.2Hz,2H),7.65(ddd,J＝9.6,8.6,1.9Hz,3H),7.53-7.46(m,1H),7.45-7.30(m,5H),7.25-7.14(m,2H),6.64-6.43(m,3H),5.32(s,2H),4.72(d,J＝23.4Hz,2H),4.40-4.23(m,4H),3.61-3.53(m,2H),3.51-3.41(m,12H),3.41-3.30(m,4H),3.19-3.12(m,2H),3.03(d,J＝4.6Hz,2H),2.97(td,J＝6.6,3.9Hz,2H),2.76(dd,J＝11.9,5.0Hz,2H),2.73-2.59(m,8H),2.55(s,3H),2.42-2.31(m,2H),2.10-1.91(m,4H),1.80-1.71(m,2H),1.65(d,J＝2.0Hz,12H)。
实施例4：YQ-H-05的合成
Figure PCTCN2022091632-appb-000007
合成方法参考YQ-H-03，结构经质谱和核磁氢谱确证，m/z＝， 1H NMR(300MHz,DMSO)δ8.95(t,J＝2.6Hz,2H),8.67(d,J＝14.1Hz,2H),8.37(dd,J＝12.4,3.7Hz,1H), 7.99(dd,J＝7.1,3.6Hz,1H),7.96-7.88(m,2H),7.75(d,J＝1.0Hz,2H),7.70-7.59(m,3H),7.54-7.30(m,6H),7.25-7.14(m,2H),6.66-6.42(m,3H),5.32(s,2H),4.73(d,J＝23.7Hz,2H),4.33(s,4H),3.59-3.54(m,2H),3.51–3.41(m,20H),3.36(dd,J＝11.4,5.8Hz,4H),3.19-3.11(m,2H),3.03(s,2H),2.98(d,J＝6.8Hz,2H),2.77(dd,J＝11.5,5.5Hz,2H),2.61(dd,J＝18.9,12.8Hz,8H),2.52(d,J＝1.6Hz,3H),2.36(t,J＝6.9Hz,2H),2.01(dd,J＝13.8,7.4Hz,4H),1.76(d,J＝3.2Hz,2H),1.68(d,J＝10.9Hz,12H)。
实施例5：YQ-H-06的合成
Figure PCTCN2022091632-appb-000008
合成方法参考YQ-H-03，结构经质谱和核磁氢谱确证，m/z＝， 1H NMR(300MHz,DMSO)δ8.95(s,2H),8.68(dd,J＝13.9,6.0Hz,2H),8.49-8.38(m,1H),8.32-8.11(m,4H),7.90(dd,J＝7.0,2.9Hz,2H),7.76(s,2H),7.65(dd,J＝12.0,5.6Hz,3H),7.52-7.44(m,1H),7.44-7.30(m,5H),7.21(dd,J＝11.5,5.7Hz,2H),6.71-6.42(m,3H),5.32(s,2H),4.78-4.63(m,2H),4.32m,4H),4.16(m,2H),3.48-3.25(m,6H),3.17(s,2H),3.09-2.99(m,4H),2.76-2.56(m,8H),2.52(s,3H),2.45(m,2H),2.02(m,4H),1.76(m,2H),1.72-1.55(m,12H)。
实施例6：YQ-H-07的合成
Figure PCTCN2022091632-appb-000009
合成方法参考YQ-H-03，结构经质谱和核磁氢谱确证，m/z＝， 1HNMR(300MHz,DMSO)δ8.94(s,2H),8.67(d,J＝14.0Hz,2H),8.51-7.99(m,8H),7.90(dd,J＝5.4,2.8Hz,2H),7.77(s,2H),7.63(d,J＝8.4Hz,3H),7.53-7.29(m,6H),7.25-7.15(m,2H),6.72-6.41(m,3H),5.32(s,2H),4.80-4.65(m,2H),4.38-4.20(m,6H),3.71(d,J＝4.9Hz,12H),3.35(p,J＝7.9Hz,2H),3.03(s,2H),3.00-2.92(m,2H),2.65(dd,J＝13.6,8.1Hz,8H),2.55(s,3H),2.43(dd,J＝8.7,2.8Hz,2H),2.11-1.94(m,4H),1.84-1.73(m,2H),1.66(s,12H)。
实施例7：YQ-H-08的合成
Figure PCTCN2022091632-appb-000010
合成方法参考YQ-H-03，结构经质谱和核磁氢谱确证，m/z＝， 1HNMR(300MHz,DMSO)δ8.94(d,J＝3.5Hz,2H),8.42(dd,J＝28.0,9.0Hz,1H),8.22-8.02(m,6H),7.94-7.86(m,2H),7.76(dd,J＝13.8,7.2Hz,2H),7.68-7.56(m,5H),7.49(td,J＝8.0,6.1Hz,1H),7.37(dd,J＝12.7,9.3Hz,5H),7.20(dd,J＝9.0,6.1Hz,4H),7.01(t,J＝7.3Hz,2H),6.63(dd,J＝43.4,3.1Hz,1H),6.34(d,J＝14.4Hz,2H),5.32(s,2H),4.73(d,J＝15.3Hz,2H),4.21(d,J＝33.3Hz,6H),3.78-3.64(m,12H),3.36(dd,J＝12.9,5.9Hz,2H),3.03(s,2H),2.83-2.64(m,6H),2.59(t,J＝6.5Hz,4H),2.55(s,3H),2.35(dd,J＝13.1,5.9Hz,2H),2.05-1.91(m, 4H),1.91-1.80(m,2H),1.22(d,J＝4.2Hz,12H)。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
实施例8
在皮下瘤HT29荷瘤鼠模型中，分别尾静脉给药YQ-H(30nmol，注射用生理盐水100uL溶解)系列探针,小动物活体成像CCD分别拍摄不同时间点荧光成像，依次是0h(给药前)，6h，12h，24h，48h，结果显示在HT29荷瘤鼠中，探针YQ-H-01/03具有一定肿瘤靶向作用的同时在肝脏等有较强的荧光信号，可能不利于后续探针开发；探针YQ-H-08，在靶向分子拉帕替尼和荧光染料之间引入芳香苯环结构，一定程度上增强了肿瘤摄取，同时也导致小鼠全身信号明显，可能是脂溶性增强导致探针体内代谢时间延长所致；探针YQ-H-04/06/07表现出更好的体内代谢特点，肝脏部位荧光信号显著减少，肿瘤部位荧光信号明显，以探针YQ-H-06肿瘤效果更优，具备后续开发的潜力。
在此基础上，本发明对探针YQ-H-06进行胰腺癌(PANC1)、肝癌(HepG2)、肺癌(H460)荷瘤鼠肿瘤靶向验证，发现探针YQ-H-06在这三种皮下瘤荷瘤鼠上同样具有较好的肿瘤靶向作用，需进一步研究开发，以期应用于临床手术导航。

Claims (9)

  1. 一种特异性靶向肿瘤的近红外荧光探针，其特征在于：其为下式Ⅰ所示的化合物或其药学可接受的盐：
    Figure PCTCN2022091632-appb-100001
    其中：
    X是连接分子，选自无、PEG n、甘氨酸G m，n＝0-10，m＝0-10，连接分子的一端为氨基，另一端为羧基；
    Y是在近红外范围内具有荧光激发和发射光谱的染料分子，且式Ⅰ所示的化合物或其药学可接受的盐能够维持或增强染料分子Y的荧光。
  2. 根据权利要求1所述的特异性靶向肿瘤的近红外荧光探针，其特征在于：所述连接分子选自PEG4、PEG6、6-氨基己酸、甘氨酸G3、甘氨酸G6、PEG4-甘氨酸，结构式如下：
    Figure PCTCN2022091632-appb-100002
  3. 根据权利要求1所述的特异性靶向肿瘤的近红外荧光探针，其特征在于：所述染料分子Y选自以下结构：
    Figure PCTCN2022091632-appb-100003
  4. 一种权利要求1-3任一所述的特异性靶向肿瘤的近红外荧光探针的合成方法，其特征在于：包括以下步骤：
    步骤a，在2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯、碱和极性溶剂的存在下混合拉帕替尼和X；
    步骤b，将步骤a得到的产物滴到水中，萃取后浓缩，再加三氟乙酸脱BOC保护基，浓缩得到拉帕替尼-X中间体化合物；
    步骤c，在2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯、碱和极性溶剂的存在下混合拉帕替尼-X中间体化合物和染料分子Y；
    步骤d，将步骤c得到的产物以制备液相纯化，得到目标化合物拉帕替尼-X-Y，即为所述近红外荧光探针。
  5. 根据权利要求4所述的特异性靶向肿瘤的近红外荧光探针的合成方法，其特征在于：所述步骤a和c中，极性溶剂为N,N-二甲基甲酰胺、无水二甲基亚砜、N-甲基吡咯烷酮的一种或多种。
  6. 根据权利要求4所述的特异性靶向肿瘤的近红外荧光探针的合成方法，其特征在于：所述步骤a和c中，碱为三乙胺、N,N-二异丙基乙胺(DIEA)的一种或多种。
  7. 权利要求1所述的特异性靶向肿瘤的近红外荧光探针在制备肿瘤诊断试剂中应用。
  8. 权利要求1所述的特异性靶向肿瘤的近红外荧光探针在制备肿瘤精准手术导航的活体荧光成像试剂中的应用。
  9. 根据权利要求8所述的应用，其特征在于：所述肿瘤为肝癌、乳腺癌、肺癌、胰腺癌、结直肠癌的一种或多种。
PCT/CN2022/091632 2022-03-01 2022-05-09 特异性靶向肿瘤的近红外荧光探针及其合成方法和应用 WO2023165015A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22754275.0A EP4269407A1 (en) 2022-03-01 2022-05-09 Near-infrared fluorescent probe specifically targeting tumor, synthesis method therefor, and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210191870.6A CN114249717B (zh) 2022-03-01 2022-03-01 特异性靶向肿瘤的近红外荧光探针及其合成方法和应用
CN202210191870.6 2022-03-01

Publications (1)

Publication Number Publication Date
WO2023165015A1 true WO2023165015A1 (zh) 2023-09-07

Family

ID=80797182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/091632 WO2023165015A1 (zh) 2022-03-01 2022-05-09 特异性靶向肿瘤的近红外荧光探针及其合成方法和应用

Country Status (3)

Country Link
EP (1) EP4269407A1 (zh)
CN (1) CN114249717B (zh)
WO (1) WO2023165015A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114249717B (zh) * 2022-03-01 2022-05-13 南京诺源医疗器械有限公司 特异性靶向肿瘤的近红外荧光探针及其合成方法和应用
CN116731021A (zh) * 2023-06-14 2023-09-12 河北医科大学 用于肿瘤靶向成像的荧光探针化合物及其合成方法和应用
CN116621823B (zh) * 2023-07-06 2023-10-31 南京诺源医疗器械有限公司 诊断转移***近红外荧光示踪剂、合成方法及应用
CN117586174B (zh) * 2024-01-19 2024-05-10 中国药科大学 用于诊断结直肠癌的近红外荧光探针及其制法和应用
CN117800951B (zh) * 2024-02-27 2024-05-28 南京诺源医疗器械有限公司 一种近红外荧光探针及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101440282A (zh) * 2008-12-18 2009-05-27 中国药科大学 近红外荧光分子探针及其合成方法和用途
WO2010009886A1 (en) * 2008-07-24 2010-01-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fluorescently or spin-labeled kinases for rapid screening and identification of novel kinase inhibitor scaffolds
CN107670050A (zh) * 2017-08-30 2018-02-09 重庆阿普格雷生物科技有限公司 基于pki‑587的抗癌中间体和聚乙二醇偶联抗癌药物、及其制备方法和应用
KR20190014625A (ko) * 2017-08-03 2019-02-13 (주)바이오액츠 형광 화합물 및 이의 제조방법
CN114249717A (zh) * 2022-03-01 2022-03-29 南京诺源医疗器械有限公司 特异性靶向肿瘤的近红外荧光探针及其合成方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009886A1 (en) * 2008-07-24 2010-01-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fluorescently or spin-labeled kinases for rapid screening and identification of novel kinase inhibitor scaffolds
CN101440282A (zh) * 2008-12-18 2009-05-27 中国药科大学 近红外荧光分子探针及其合成方法和用途
KR20190014625A (ko) * 2017-08-03 2019-02-13 (주)바이오액츠 형광 화합물 및 이의 제조방법
CN107670050A (zh) * 2017-08-30 2018-02-09 重庆阿普格雷生物科技有限公司 基于pki‑587的抗癌中间体和聚乙二醇偶联抗癌药物、及其制备方法和应用
CN114249717A (zh) * 2022-03-01 2022-03-29 南京诺源医疗器械有限公司 特异性靶向肿瘤的近红外荧光探针及其合成方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARROTT, JARED J. ET AL.: "Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells", CHEMISTRY & BIOLOGY, vol. 20, no. 9, 19 September 2013 (2013-09-19), pages 1187 - 1197, XP093019223 *

Also Published As

Publication number Publication date
EP4269407A1 (en) 2023-11-01
CN114249717A (zh) 2022-03-29
CN114249717B (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
WO2023165015A1 (zh) 特异性靶向肿瘤的近红外荧光探针及其合成方法和应用
DK168296B1 (da) Fluorescerende mono-, di- eller polyamider af en amino-monocarboxylsyre og en tetrapyrrolforbindelse samt anvendelse af disse til fremstilling af et farmaceutisk præparat til fotodiagnose og/eller fototerapi af tumorer
CN109010826B (zh) 一种基于吲哚方酸菁染料的靶向材料及其制备方法和荧光纳米粒子及其制备方法
TW201630627A (zh) 纖維化疾病之造影劑
JP7308366B2 (ja) アクティブターゲティング型葉酸受容体近赤外蛍光分子及びその調製方法
CN111004307B (zh) 一种治疗早期脑胶质瘤的吲哚菁绿类化合物及其制备方法和应用
WO2020228627A1 (zh) 一种新型双模态小分子造影剂及其制备方法与应用
EP3710068A1 (en) A double-labeled probe for molecular imaging and use thereof
CN117800951B (zh) 一种近红外荧光探针及其制备方法与应用
CN113149966A (zh) Nir/pet双模态造影剂及其制备方法与应用
JP2010203966A (ja) 低酸素領域イメージング用近赤外蛍光プローブ
CN111363007A (zh) 一种高效主动靶向近红外荧光示踪剂的合成方法
CN102321159A (zh) 一种具有肿瘤靶向性的光敏剂及其制备方法
WO2022063208A1 (zh) 一种官能化双嵌段共聚物及其制备方法和用途
US20230277699A1 (en) Tumor stroma imaging agent and preparation method thereof
CN113149967A (zh) Nir/mri双模态造影剂及其制备方法与应用
CN113425859B (zh) 一种GnRH多肽修饰的探针、包含它的制剂、药物组合物及其制备方法与应用
CN115572320B (zh) 一种***癌分子探针及其制备方法与应用
WO2022242437A1 (zh) 一种荧光-磁共振双模态造影剂及其制备方法和用途
CN113717543B (zh) 一种七甲川菁近红外染料及其应用
CN113004254B (zh) 以吲哚氰绿衍生物为载体的配体及其制备方法与应用
WO2022037599A9 (zh) 二氢卟吩衍生物或其可药用盐、其制备方法、用途、及其与超声医疗***的组合
WO2022193186A1 (en) New diagnostic and therapeutic agents
CN118048050A (zh) 一种七甲川菁近红外荧光染料及其制备方法和应用
WO2024012157A1 (zh) 一种多肽类化合物及其配合物、应用

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2022754275

Country of ref document: EP

Effective date: 20220824